Although pharmacological inhibition of the TGFβ pathway is beneficial for FA HPSCs, rescuing several of the FA HSPCs phenotypes, this may not be the case when the TGFβ pathway is genetically abrogated at the organismal level [13]. This evidence concerns the gene TGFB1 and Friedreich ataxia.